Jitendra – Page 2 – Scilex Holding

20 Dec

Press Release

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

December 27, 2023
Posted by Jitendra

06 Dec

Press Release

Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State

December 6, 2023
Posted by Jitendra

04 Dec

Press Release

Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee

December 6, 2023
Posted by Jitendra

28 Nov

Press Release

Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.

November 28, 2023
Posted by Jitendra

27 Nov

Press Release

Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024

November 27, 2023
Posted by Jitendra

22 Nov

Press Release

Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Cal

November 22, 2023
Posted by Jitendra

21 Nov

Press Release

Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB®

November 21, 2023
Posted by Jitendra

17 Nov

Press Release

Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch

November 20, 2023
Posted by Jitendra

15 Nov

Press Release

Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch

November 20, 2023
Posted by Jitendra

Topical Delivery Systems Effectively Transport Analgesics to Areas of Localized Pain via Direct Diffusion

January 31, 2024
Posted by Jitendra

Posts by Jitendra

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State

Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee

Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.

Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024

Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Cal

Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB®

Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch

Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch

Topical Delivery Systems Effectively Transport Analgesics to Areas of Localized Pain via Direct Diffusion

Gloperba Launch – Nasdaq-2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

Gout Awareness Day – May 22

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch